Accounting for equity considerations in cost-effectiveness analysis: a systematic review of rotavirus vaccine in low- and middle-income countries
Tóm tắt
Cost-effectiveness analysis (CEA) is frequently used as an input for guiding priority setting in health. However, CEA seldom incorporates information about trade-offs between total health gains and equity impacts of interventions. This study investigates to what extent equity considerations have been taken into account in CEA in low- and middle-income countries (LMICs), using rotavirus vaccination as a case study. Specific equity-related indicators for vaccination were first mapped to the Guidance on Priority Setting in Health Care (GPS-Health) checklist criteria. Economic evaluations of rotavirus vaccine in LMICs identified via a systematic review of the literature were assessed to explore the extent to which equity was considered in the research objectives and analysis, and whether it was reflected in the evaluation results. The mapping process resulted in 18 unique indicators. Under the ‘disease and intervention’ criteria, severity of illness was incorporated in 75% of the articles, age distribution of the disease in 70%, and presence of comorbidities in 5%. For the ‘social groups’ criteria, relative coverage reflecting wealth-based coverage inequality was taken into account in 30% of the articles, geographic location in 27%, household income level in 8%, and sex at birth in 5%. For the criteria of ‘protection against the financial and social effects of ill health’, age weighting was incorporated in 43% of the articles, societal perspective in 58%, caregiver’s loss of productivity in 45%, and financial risk protection in 5%. Overall, some articles incorporated the indicators in their model inputs (20%) while the majority (80%) presented results (costs, health outcomes, or incremental cost-effectiveness ratios) differentiated according to the indicators. Critically, less than a fifth (17%) of articles incorporating indicators did so due to an explicit study objective related to capturing equity considerations. Most indicators were increasingly incorporated over time, with a notable exception of age-weighting of DALYs. Integrating equity criteria in CEA can help policy-makers better understand the distributional impact of health interventions. This study illustrates how equity considerations are currently being incorporated within CEA of rotavirus vaccination and highlights the components of equity that have been used in studies in LMICs. Areas for further improvement are identified.
Tài liệu tham khảo
Martin CM, Kaufman T. Addressing health inequities: a case for implementing primary health care. Can Fam Physician. 2008;54(11):1515–7.
O’Donnel O, van Doorslaer E, Wagstaff A, Lindelow M. Analyzing health equity using household survey data. The World Bank. Washington, D.C.: WBI Learning Resources; 2008.
Braveman P, Gruskin S. Defining equity in health. J Epidemiol Community Health. 2003;57:254–8.
Culyer AJ. Efficiency, equity and equality in health and health care. In: CHE Research Paper 120; 2015.
Braveman P. Health disparities and health equity: concepts and measurement. Annu Rev Public Health. 2006;27:167–94.
Östlin P, Schrecker T, Sadana R, Bonnefoy J, Gilson L, Hertzman C, et al. Priorities for research on equity and health: towards an equity-focused health research agenda. PLoS Med. 2011;8:11.
Johri M, Norheim OF. Can cost-effectiveness analysis integrate concerns for equity? Systematic review. Int J Technol Assess Health Care. 2012;28(2):125–32.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1–5.
Shah KK, Cookson R, Culyer AJ, Littlejohns P. NICE’s social value judgements about equity in health and health care. Health Econ Policy Law. 2013;8(2):145–65.
Claxton KP, Revill P, Sculpher M, Wilkinson T, Cairns J, Briggs A. The gates reference case for economic evaluation. The Bill and Melinda Gates Foundation; 2014. p. 68.
Sassi F, Archard L, Le Grand J. Equity and the economic evaluation of healthcare. Health Technol Assess. 2001;5(3):1–38.
Hauck KS, Smith AC, Goddard M. The economics of priority setting for health care: a literature review. HNP Discussion Paper; 2004.
Cookson R, Mirelman AJ, Griffin S, Asaria M, Dawkins B, Norheim OF, et al. Using cost-effectiveness analysis to address health equity concerns. Value Health. 2017;20(2):206–12.
Asaria M, Griffin S, Cookson R. Distributional cost-effectiveness analysis: a tutorial. Med Decis Making. 2016;36(1):8–19.
Verguet S, Laxminarayan R, Jamison DT. Universal public finance of tuberculosis treatment in India: an extended cost-effectiveness analysis. Health Econ. 2015;24(3):318–32.
Verguet S, Kim JJ, Jamison DT. Extended cost-effectiveness analysis for health policy assessment: a tutorial. Pharmacoeconomics. 2016;34(9):913–23.
Jamison DT. Cost-effectiveness analysis: concept and applications, vol. 4. Oxford: Oxford University Press; 2002.
Norheim OF, Baltussen R, Johri M, Chisholm D, Nord E, Brock D, et al. Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis. Cost Eff Resour Alloc. 2014;12:18.
Glassman A, Cañón O, Silverman R. How to get cost-effectiveness analysis right? The case of vaccine economics in Latin America. Value Health. 2016;19(8):913–20.
Gandhi G. Charting the evolution of approaches employed by the Global Alliance for Vaccines and Immunizations (GAVI) to address inequities in access to immunization: a systematic qualitative review of GAVI policies, strategies and resource allocation mechanisms through an equity lens (1999–2014). BMC Public Health. 2015;15:1198.
World Health Organization. Rotavirus Vaccines. WHO position paper—January 2013. Wkly Epidemiol Rec. 2013;5(88):49–64.
Ahs JW, Tao W, Löfgren J, Forsberg BC. Diarrheal diseases in low- and middle-income countries: incidence, prevention and management. Open Infect Dis J. 2010;4:113–24.
World Health Organization: Estimated rotavirus deaths for children under 5 years of age: 2013, 215000. http://www.who.int/immunization/monitoring_surveillance/burden/estimates/rotavirus/en/. Accessed 10 Sept 2017.
International Vaccine Access Center (IVAC), Johns Hopkins Bloomberg School of Public Health. VIEW-hub. https://www.view-hub.org. Accessed 20 Oct 2017.
Carvalho N, Jit M, Cox S, Yoong J, Hutubessy RCW. Capturing budget impact considerations within economic evaluations: a systematic review of economic evaluations of rotavirus vaccine in Low- and Middle-Income Countries and a proposed assessment framework. Pharmacoeconomics. 2017. https://doi.org/10.1007/s40273-017-0569-2.
Whitehead M. The concepts and principles of equity and health. Int J Health Serv. 1991;22(3):429–45.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
Nord E. Severity of illness versus expected benefit in societal evaluation of healthcare interventions. Expert Rev Pharmacoecon Outcome Res. 2001;1(1):85–92.
Van Man N, Le Luan T, Trach DD, Thanh NT, Van Tu P, Long NT, et al. Epidemiological profile and burden of rotavirus diarrhea in Vietnam: 5 Years of sentinel hospital surveillance, 1998–2003. J Infect Dis. 2005;194(Suppl1):S127–32. https://doi.org/10.1086/431501.
Hanvoravongchai P. Health system and equity perspectives in health technology assessment. J Med Assoc Thai. 2008;91(Suppl 2):S74–87.
Hope T. Rationing and life-saving treatments: should identifiable patients have higher priority? J Med Ethics. 2001;27(3):179–85.
Moura FL, Goulart PR, Moura AP, Souza TS, Fonseca AB, Amendoeira MR. Factors associated to toxoplasmosis-related knowledge among pregnant women attending public health services in the municipality of Niteroi, Rio de Janeiro, Brazil, 2013–2015. Epidemiol Serv Saude. 2016;25(3):655–61.
Megiddo I, Colson AR, Nandi A, Chatterjee S, Prinja S, Khera A, et al. Analysis of the universal immunization programme and introduction of a rotavirus vaccine in India with IndiaSim. Vaccine. 2014;32(Suppl 1):A151–61. https://doi.org/10.5123/S1679-49742016000300022.
Arsenault C, Harper S, Nandi A, Rodriguez JM, Hansen PM, Johri M. An equity dashboard to monitor vaccination coverage. Bull World Health Organ. 2017;95(2):128–34.
Uruena A, Pippo T, Betelu MS, Virgilio F, Hernandez L, Giglio N, et al. Cost-effectiveness analysis of rotavirus vaccination in Argentina. Vaccine. 2015;33(Suppl 1):A126–34.
Quintal C. Aversion to geographic inequality and geographic variation in preferences in the context of healthcare. Appl Health Econ Health Policy. 2009;7(2):121–36.
Devlin N, Sussex J. Incorporating multiple criteria in HTA: methods and processes. Office of Health Economics; 2011. https://www.ohe.org/publications/incorporating-multiple-criteria-hta-methods-and-processes. Accessed 20 June 2017.
Newman PA, Logie CH, Doukas N, Asakura K. HPV vaccine acceptability among men: a systematic review and meta-analysis. Sex Transm Infect. 2013;89(7):568–74.
Krol M, Brouwer W. How to estimate productivity costs in economic evaluations. Pharmacoeconomics. 2014;32(4):335–44. https://doi.org/10.1007/s40273-014-0132-3.
World Health Organization. WHO methods and data sources for global burden of disease estimates 2000–2015. In: Global Health Estimates Technical Paper WHO/HIS/IER/GHE/2016.2. http://www.who.int/healthinfo/statistics/LT_method.pdf. Accessed 21 Dec 2017.
Donev D, Zaletel-Kragelj L, Bjegovic V, Burazeri G. Measuring the burden of disease: disability adjusted life years (DALY) [online]. Available: http://www.mf.uni-lj.si/dokumenti/6b695fc9385e3e2ab8fb41ec7d34660d.pdf. Accessed 20 Dec 2017.
Murray C, Acharya A. Age weights and discounting in health gaps reconsidered. In: Murray CJL, Solomon JA, Mathers CD, Lopez AD, editors. Summary measures of population health: concepts, ethics, measurement and applications. Geneva: World Health Organization; 2002. p. 677–84.
Chen A, Jacobsen KH, Deshmukh AA, Cantor SB. The evolution of the disability-adjusted life year (DALY). SocioEcon Plan Sci. 2015;49:10–5.
Xu K, Evans DB, Kawabata K, Zeramdini R, Klavus J, Murray CJL. Household catastrophic health expenditure: a multicountry analysis. Lancet. 2003;362(9378):111–7.
Saksena P, Hsu J, Evans DB. Financial risk protection and universal health coverage: evidence and measurement challenges. PLoS Med. 2014;11(9):e1001701.
Kirkwood CD, Steele AD. Rotavirus vaccine will have an impact in Asia. PLoS Med. 2017;14(5):e1002298.
Marti SG, Alcaraz A, Valanzasca P, McMullen M, Standaert B, Garay U, et al. Cost effectiveness evaluation of a rotavirus vaccination program in Argentina. Vaccine. 2015;33(42):5684–90.
Pecenka CJ, Johansson KA, Memirie ST, Jamison DT, Verguet S. Health gains and financial risk protection: an extended cost-effectiveness analysis of treatment and prevention of diarrhoea in Ethiopia. BMJ Open. 2015;5(4):e006402.
Rheingans R, Atherly D, Anderson J. Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness. Vaccine. 2012;30(Suppl 1):A15–23.
Diop A, Atherly D, Faye A, Lamine Sall F, Clark AD, Nadiel L, et al. Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: a country-led analysis. Vaccine. 2015;33(Suppl 1):A119–25.
Clark A, Jauregui B, Griffiths U, Janusz CB, Bolanos-Sierra B, Hajjeh R, Andrus JK, Sanderson C. TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination. Vaccine. 2013;31(Suppl 3):C19–29.
Rheingans R, Amaya M, Anderson JD, Chakraborty P, Atem J. Systematic review of the economic value of diarrheal vaccines. Hum Vaccin Immunother. 2014;10(6):1582–94.
Wilopo SA, Kilgore P, Kosen S, Soenarto Y, Aminah S, Cahyono A, Ulfa M, Tholib A. Economic evaluation of a routine rotavirus vaccination programme in Indonesia. Vaccine. 2009;27(Suppl 5):F67–74.
Rheingans R. Anderson JDt, Anderson B, Chakraborty P, Atherly D, Pindolia D. Estimated impact and cost-effectiveness of rotavirus vaccination in India: effects of geographic and economic disparities. Vaccine. 2014;32(Suppl1):A140–50.
Isakbaeva ET, Musabaev E, Antil L, Rheingans R, Juraev R, Glass RI, et al. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Vaccine. 2007;25(2):373–80.
Verguet S, Murphy S, Anderson B, Johansson KA, Glass R, Rheingans R. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis. Vaccine. 2013;31(42):4902–10.
Verguet S, Olson ZD, Babigumira JB, Desalegn D, Johansson KA, Kruk ME, Levin CE, Nugent RA, Pecenka C, Shrime MG, et al. Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis. Lancet Global Health. 2015;3(5):e288–96.
Nuti S, Vainieri M, Vola F. Priorities and targets: supporting target-setting in healthcare. Public Money Manag. 2017;37(4):277–84.
Lim MK, Bae EY, Choi SE, Lee EK, Lee TJ. Eliciting public preference for health-care resource allocation in South Korea. Value Health. 2012;15(1 Suppl):S91–4.
Kapiriri L, Norheim OF. Criteria for priority-setting in health care in Uganda: exploration of stakeholders’ values. Bull World Health Org. 2004;82(3):172–9.
Shah KK. Severity of illness and priority setting in healthcare: a review of the literature. Health Policy. 2009;93(2–3):77–84.